Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by World Investment Advisors LLC

World Investment Advisors LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 33.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 25,999 shares of the biopharmaceutical company's stock after acquiring an additional 6,535 shares during the quarter. World Investment Advisors LLC's holdings in Gilead Sciences were worth $2,180,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in GILD. Lantz Financial LLC grew its holdings in shares of Gilead Sciences by 3.5% in the second quarter. Lantz Financial LLC now owns 24,920 shares of the biopharmaceutical company's stock valued at $1,710,000 after purchasing an additional 840 shares in the last quarter. Blue Trust Inc. lifted its holdings in Gilead Sciences by 280.3% during the 2nd quarter. Blue Trust Inc. now owns 4,712 shares of the biopharmaceutical company's stock worth $345,000 after buying an additional 3,473 shares during the last quarter. Gradient Investments LLC boosted its position in shares of Gilead Sciences by 133.6% during the 2nd quarter. Gradient Investments LLC now owns 619 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 354 shares in the last quarter. Raymond James & Associates increased its stake in Gilead Sciences by 13.4% in the second quarter. Raymond James & Associates now owns 2,302,754 shares of the biopharmaceutical company's stock valued at $157,992,000 after purchasing an additional 271,545 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its position in shares of Gilead Sciences by 2.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 355,953 shares of the biopharmaceutical company's stock valued at $24,422,000 after buying an additional 8,529 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences Price Performance

Shares of GILD stock traded up $0.24 during trading hours on Friday, hitting $91.86. The company's stock had a trading volume of 7,515,462 shares, compared to its average volume of 7,068,425. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The business has a fifty day moving average of $89.96 and a 200-day moving average of $79.55. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The stock has a market cap of $114.48 billion, a price-to-earnings ratio of 1,020.61, a P/E/G ratio of 2.38 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating analysts' consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion for the quarter, compared to analysts' expectations of $7.01 billion. During the same quarter in the prior year, the firm earned $2.29 EPS. Gilead Sciences's quarterly revenue was up 7.0% on a year-over-year basis. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 4.35 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be issued a $0.77 dividend. The ex-dividend date of this dividend is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.35%. Gilead Sciences's dividend payout ratio (DPR) is 3,422.22%.

Analyst Ratings Changes

A number of research analysts recently issued reports on GILD shares. Truist Financial raised their price target on Gilead Sciences from $83.00 to $97.00 and gave the stock a "hold" rating in a research note on Friday, November 8th. Piper Sandler lifted their target price on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an "overweight" rating in a report on Thursday, November 7th. UBS Group increased their price target on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a "neutral" rating in a research note on Thursday, November 21st. Oppenheimer lifted their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an "outperform" rating in a research note on Tuesday, December 10th. Finally, Maxim Group cut Gilead Sciences from a "buy" rating to a "hold" rating in a research report on Friday, November 8th. Twelve research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of "Moderate Buy" and an average price target of $96.43.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 248,645 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the transaction, the chief financial officer now directly owns 138,919 shares in the company, valued at $12,886,126.44. This represents a 64.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Merdad Parsey sold 25,590 shares of the business's stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the sale, the insider now owns 99,599 shares of the company's stock, valued at approximately $9,113,308.50. The trade was a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 447,234 shares of company stock valued at $41,288,086 in the last ninety days. Insiders own 0.16% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.